AbstractIn the development of essential hypertension cardiac remodeling is determined by both hemodynamic and neurohumoral factors. The influence of hemodynamic factors is sufficiently studied, while the role of stimulating and inhibiting humoral agents in the development of cardiac remodeling is completely unknown. Therefore, the study of structural and functional indicators of the myocardial state in patients with essential hypertension and heart failure being carriers of different BNP genotypes is promising in terms of the possible role of the BNP gene polymorphisms in the development and progression of cardiac disease manifestations.The objective of the research was to examine structural and functional indicators of the myocardial state in men with essential hypertension and co-existent chronic heart failure Class IIА being carriers of different variants of the brain natriuretic peptide gene at the age of 40-60 years living in Podillia region.Materials and methods. Genotyping of the brain natriuretic peptide gene was performed using the polymerase chain reaction. Structural and functional indicators of the myocardial state were assessed by cardiac ultrasound with ultrasound device ULTIMA RA (Radmir, Ukraine).Results. The results revealed that among men with stage II essential hypertension the frequency of the T381T genotype of the brain natriuretic peptide gene was 35.48% and 64.52% of patients were carriers of C allele (р<0.001); among patients with essential hypertension and co-existent chronic heart failure Class IIА the frequency of the T381T genotype was 42.00% and 58.00% of patients were carriers of C allele (р≤0.05). In patients with chronic heart failure Class IIА being carriers of the T381T genotype the size and volume of the left ventricle at the end of systole and diastole were significantly larger, the indicators of the left ventricular myocardium mass index and left ventricular wall thickness were higher than in carriers of C allele (р<0.05). The indicators of the size and volume of the left ventricle, posterior left ventricular wall thickness and systemic hemodynamics regardless of the brain natriuretic peptide genotype were significantly higher in men with essential hypertension and co-existent chronic heart failure Class IIА compared to patients with stage II essential hypertension (p<0.05).Conclusion. In patients with symptoms of chronic heart failure Class IIA being carriers of the Т381Т genotype the size and volume of the left ventricle at the end of systole and diastole were significantly larger, the indicators of the left ventricular myocardium mass index and left ventricular wall thickness were higher than in carriers of C allele of the brain natriuretic peptide gene (р<0.05). In patients with essential hypertension and co-existent chronic heart failure Class IIА EF<45% being carriers of the Т381Т genotype, the highest indicators of the size of the left ventricle, end-systolic volume index, end-diastolic volume index, left ventricular myocardium mass index were observed. The inheritance of the T381T genotype by patients with symptoms of chronic heart failure Class IIA was found to be associated with higher levels of systolic blood pressure and diastolic blood pressure irrespective of the state of left ventricular systolic function.
Berezikova EN, Mayanskaya SD, Garaeva LA, Shilov SN, Efremov AV, Teplyakov AT, et al. Polimorfism gena mozgovogo natriyureticheskogo peptide u bolnikh s khronicheskoy serdechnoy nedostatochnostyu. Kazanskiy meditsinskiy zhurnal. 2013;4:433-438.
Berezin AE. Biologicheskie markery pri khronicheskoy serdechnoy nedostatochnosti: ozhidaniya, realnost, perspektivy. Sertseva nedostatnist. 2013;1:5-15.
Blanar OL, Zhebel VM. Spadkovist ta strukturno-funktsionalni zminy sertsia u khvorykh na hipertonichnu khvorobu, uskladnenu sertsevoiu nedostatnistiu. Simeina medytsyna.2009;2:79-85.
Voronkov LG. Patsiient iz KhSN v Ukraiini: analiz danykh populiatsii patsientiv, obstezhenykh u ramkakh pershoho natsionalnoho zrizovoho doslidzhennia UNIVERS. Sertseva nedostatnist. 2012;1(1):8-13.
Voronkov LG. Shliakh patsientiv z khronichnoiu sertsevoiu nedostatnistiu: yakomoha dovshyi, yakomoha komfortnishyi. Sertseva nedostatnist. 2014;1:7-10.
Mitchenko OI, Romanov VYu, Ilyushina GYa. Realizatsiia mizhnarodnykh rekomendatsii shchodo profilaktyky sertsevo-sudynnukh zakhvoriuvan u zhinok: focus na omeha-3-polinenasycheni zhyrni kysloty. Ukr med chasopys: naukovo-praktychnyi zahalno medychnyi zhurnal. 2013;2:107-115.
Zhebel VM, Starzhynska ОL, Hefter YuO, et al. Henotyp retseptora do anhiotenzynu II 1-ho typu yak faktor vplyvu na strukturu ta funktsiiu miokarda u khvorykh na hipertonichnu khvorobu riznoii vazhkosti. Arterialna hipertenziia. 2009;1(3):24-29.
Costello-Boerrigter LC, Boerrigter G, Ameenuddin S, Mahoney DW, Slusser JP, Heublein DM, et al. The Effect of the Brain-Type Natriuretic Peptide Single-Nucleotide Polymorphism rs198389 on Test Characteristics of Common Assays. Mayo Clinic Proceedings. 2011;86(3):210-218. http://dx.doi.org/10.4065/mcp.2010.0708
Chairperson GM, Chairperson RF, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al. ESH/ESC Guidelines for the management of arterial hypertension. Journal of Hypertension. 2013;31(7):1281-1357.
Gorący I, Dawid G, Skonieczna-Żydecka K, Kaczmarczyk M, Łoniewska B, Gorący J. Association of genetic variation in the natriuretic peptide system and left ventricular mass and blood pressure in newborns. Polish Heart Journal. 2015;73(5):366-372.
Lajer M, Tarnow L, Jorsal A, Parving HH. Polymorphisms in the B-type natriuretic peptide (BNP) gene are associated with NT-proBNP levels but not with diabetic nephropathy or mortality in type 1 diabetic patients. Nephrol Dial Transplant. 2007;22(11):3235-3239. http://dx.doi.org/10.1093/ndt/gfm360
Lanfear DE. Genetic variation in the natriuretic peptide system and heart failure. Heart Fail Reviews. 2010;15(3):219-228. http://dx.doi.org/10.1007/s10741-008-9113-y
Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification. Eur J Echocardiography. 2006; 7:79-108. http://dx.doi.org/10.1016/j.euje.2005.12.014
Lumsden NG, Khambata RS, Hobbs AJ. C-type natriuretic peptide (CNP): cardiovascular roles and potential as a therapeutic target. Current Pharmaceutical Design. 2010;16(37):4080-4088. http://dx.doi.org/10.2174/138161210794519237
Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiography. 2009;10:165-193. http://dx.doi.org/10.1093/ejechocard/jep007
Nicholls MG, Richards AM. Disease monitoring of patients with chronic heart failure. Heart. 2007;93(4):519-523. http://dx.doi.org/10.1136/hrt.2005.078519
Pashkova I, Zhebel V, Palahniuk H, Sakovych O, Starzhynska O, Gumenyuk A, et al. The BNP gene polymorphism as a regulator of brain natriuretic peptide plasma level in men with uncomplicated essential hypertension and left ventricular hypertrophy. Biological Markers and Guided Therapy. 2015;2(1):13-23. http://dx.doi.org/10.12988/bmgt.2015.5101
Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland John GF, Coats Andrew JS, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2016;128:1-85.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.